---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-26-000031"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:26:02.536555+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q1 2026 GAAP net income drops 75% to $6.4M; adjusted EPS falls to $0.42

## Summary
- Net revenues flat at $171.2M vs $170.5M YoY.
- GAAP net income $6.4M ($0.14 diluted EPS) vs $25.3M ($0.51) in Q1 2025.
- Adjusted non-GAAP net income $19.5M ($0.42 diluted EPS) vs $36.9M ($0.74).
- Launched Ipratropium Bromide HFA; signed license for synthetic corticotropin compound.

## SEC filing metadata
- accession: 0001297184-26-000031
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/0001297184-26-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/amph-20260507x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-26-000031
- JSON: https://secwatch.observer/filing/0001297184-26-000031.json
- Plain text: https://secwatch.observer/filing/0001297184-26-000031.txt

## Source-grounded claims
- claim_id: 03e3d92ca837d5ebe0f3b7500a2d6eee6f80cac6
  claim: Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2026 results: net income Adjusted non-GAAP net income of $19.5 million, EPS $0.42 per share.
  evidence_excerpt: of $171.2 million for the three months ended March 31, 2026 ​ - GAAP net income of $6.4 million, or $0.14 per share, for the first quarter ​ - Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter ​ - Company to hold a conference call today at 2:00 p.m. Pacific Time ​ RANCHO CUCAMONGA, CA – May 7, 2026 – Amphastar Pharmaceuticals,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/0001297184-26-000031-index.htm
- claim_id: 03e3d92ca837d5ebe0f3b7500a2d6eee6f80cac6
  claim: Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2026 results: net income Adjusted non-GAAP net income of $19.5 million, EPS $0.42 per share.
  evidence_excerpt: Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000031/0001297184-26-000031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.